Goldman Sachs Comment on Perrigo's (PRGO) Omega Deal and Quarterly Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Perrigo (PRGO) Misses Q1 EPS by 4c
November 6, 2014 6:33 AM ESTPerrigo (NYSE: PRGO) reported Q1 EPS of $1.40, $0.04 worse than the analyst estimate of $1.44. Revenue for the quarter came in at $951.5 million versus the consensus estimate of $997.9 million.
For earnings history and earnings-related data on Perrigo (PRGO) click here.
... MorePerrigo (PRGO) to Acquire Omega Pharma in ~$4.5B Deal
November 6, 2014 6:28 AM ESTPerrigo (NYSE: PRGO) and Omega Pharma NV, one of the largest OTC healthcare companies in Europe, headquartered in Nazareth, Belgium, today announced that they have entered into a definitive agreement in which Perrigo has agreed to acquire Omega for 3.6 billion, or $4.5 billion, comprised of the purchase of Omega's equity for 2.48 billion and the assumption of 1.1 billion in debt. The transaction, funded through a combination of cash, debt, and equity, will enhance Perrigo's leading OTC product offering and expand its distribution through Omega's strong established platform.
"The combination of these two great companies accelerates Perrigo's international growth... More
